The Performance and Utility of Biochemical Markers of Bone Turnover: Do We Know Enough to Use Them in Clinical Practice?

Blumsohn A Eastell R . Biochemical assessment of skeletal activity. Phys Med Rehab Clinics N Am 1995; 6: 483–505

Hamdy NAT Papapoulos SE Colwell A Eastell R Russell RGG . Urinary collagen crosslink excretion: A better index of bone resorption than hydroxyproline in Paget's disease of bone? Bone Miner 1993; 22: 1–8

Ebeling PR Peterson JM Riggs BL . Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243–50

Hassager C Fabbri-Mabelli G Christiansen C . The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporosis Int 1993; 3: 50–2

Parfitt AM Simon LS Villanueva AR Krane SM . Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphate. J Bone Miner Res 1987; 2: 427–36

Blumsohn A Hannon RH Wrate R Barton J Al-Dehaimi AW Colwell A . Biochemical Markers of Bone Turnover in Girls During Puberty. Clin Endocrinol 1994; 40: 663–70

Blumsohn A Naylor KE Assiri AMA Eastell R . Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem 1995; 41: 1592–8

Risteli J Niemi S Kauppila S Melkko J Risteli L . Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand 1995; 66 (suppl): 1–6

Sorva A Tähtelä R Risteli L Laitinen K Backman Juntunen K . Familial high serum concentrations of the carboxy-terminal propeptide of type I collagen. Clin Chem 1994; 40: 1591–3

Garnero P Grimaux M Seguin P Delmas PD . Characterisation of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994; 9: 255–64

Blumsohn A Hannon RA Eastell R . Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 1995; 41: 318–9

Delmas PD Christiansen C Mann KG Price PA . Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res 1990; 5: 5–11

Masters PW Jones RG Purves DA Cooper EH . Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 1994; 40: 358–63

Deftos LJ Wolfert RL Hill CS Burton DW . Two-site assays of bone Gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule. Clin Chem 1992; 38: 2318–21

Diego EMD Guerrero R De la Piedra C . Six osteocalcin assays compared. Clin Chem 1994; 40: 2071–7

Crofton PM . Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: Age dependent reference ranges and changes in liver and bone disease. Clin Chem 1992; 38: 663–70

Kuwana T Sugita O Yakata M . Sugar-chain analysis of alkaline phosphatase by lectin affinity chromatography in serum from a patient with osteosarcoma. Clin Chem 1989; 35: 179

Miura M Matsuzaki H Bailyes EM Koyoma I Sakagishi Y Sekine T . Differences between human liver- and bone-type alkaline phosphatases. Clin Chim Acta 1989; 180: 177–87

Miura M Sakagishi Y Hata K Komoda T . Differences between the sugar moieties of liver-and bone-type alkaline phosphatases. Ann Clin Biochem 1994; 31: 25–30

Schoenau E Herzog KH Boehles HJ . Liquid-chromatographic determination of isoenzymes of alkaline phosphatase in serum and tissue homogenates. Clin Chem 1986; 32: 816–8

Sinha PK Bianchi-Bosiso A Meyer-Sabellek W Righerri PG . Resolution of alkaline phosphatase isoenzymes in serum by isoelectric focusing in immobilized pH gradients. Clin Chem 1986; 32: 1264–8

O'Brien JF Kottke T . Alkaline phosphatase isoenzymes: The more isoforms we resolve the more questions need resolving. Prog Clin Biochem 1992; 991: 339–43

Farley JR Hall SL Ilacas D Orcutt C Miller BE Hill CS . Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. Clin Chem 1994; 40: 1749–56

Behr W Barnert J . Quantification of bone alkaline phosphatase in serum be precipitation with wheat-germ lectin: A simplified method and its clinical plausibility. Clin Chem 1986; 32: 1960–6

Rosalki SB Foo AY . Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin Chem 1984: 30: 1182–6

Van Hoof VO De Broe ME . Interpretation and clinical significance of alkaline isoenzyme patterns. Crit Rev Clin Lab Sci 1994; 31: 197–293

Moro L Mucelli SP Gazzarrini C Modricky C Marotti F de Bernard B . Urinary β-1 galactosyl-O-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int 1988; 42: 87–90

Colwell A Russell RGG Eastell R . Factors affecting the assay of urinary 3-hydroxy pyridinium cross-links of collagen as markers of bone-resorption. Eur J Clin Invest 1993; 23: 341–9

Robins SP Woitge H Hesley R Ju J Seyedin S Seibel MJ . Direct enzyme-linked immonosorbent assay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 1643–9

Risteli J Elomaa I Niemi S Novamo A Risteli L . Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new marker of bone degradation. Clin Chem 1993; 39: 635–40

Hanson DA Weis MAE Bollen AM Maslan SL Singer FR Eyre DR . A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251–8

Bonde M Qvist P Fledelius C Riis BJ Christiansen C . Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994: 40: 2022–5

Garnero P Gineyts E Arbault P Christiansen C Delmas PD . Different effects of bisphosphonate and estrogen therapy on the excretion of free and peptide-bound crosslink excretion. J Bone Miner Res 1995; 10: 641–9

Rosen HN Dresner-Pollak R Moses AC Rosenblatt M Zeind AJ Clemens JD . Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26–9

Prestwood KM Pilbeam CC Burleson JA Woodiel FN Delmas PD Deftos LJ . The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994; 79: 366–71

Kamel S Brazier M Picard C Boitte F Samson L Desmet G . Urinary excretion of pyridinolines crosslinks measured by immunoassay and HPLC techniques in normal subjects and in elderly patients with vitamin D deficiency. Bone Miner 1994: 26: 197–208

Garnero P Shih WJ Gineyts E Karpf DB Delmas PD . Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700

Hassager C Jensen LT Pødenphant J Thomsen K Christiansen C . The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994; 54: 30–3

Filipponi P Pedetti M Beghe F Giovagnini B Miam M Cristallini S . Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed. Bone 1994; 15: 261–7

Alvarez L Guañabens N Peris P Monegal A Bedini JL Deulofeu R . Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10: 458–65

Välimäki MJ Tahtela R Jones JD Peterson JM Riggs BL . Bone resorption in healthy and osteoporotic postmenopausal women: Comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. Eur J Clin Endocrinol 1994; 131: 258–62

Reddy SV Hundley JE Windle JJ Alcantara O Linn R Leach RJ . Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res 1995; 10: 601–6

Bevilacqua MA Lord DK Cross NCP Whitaker KB Moss DW Cox TM . Regulation and expression of type V (Tartrate-resitant) acid phosphatase in human mononuclear phagocytes. Molec Biol Med 1991; 8: 135–40

Kayoda Y Al-Saffar N Kobayashi A Revell PA . The expression of osteoclast markers on foreign body giant cells. Bone Miner 1994; 27: 85–96

Cheung CK Panesar NS Haines C Masarei J Swaminathan R . Immunoassay of tartrate resistant acid phosphatase in serum. Clin Chem 1995; 41: 679–86

Echetebu ZO Cox TM Moss DW . Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase in serum. Clin Chem 1987; 33: 1832–6

Kraenzlin ME Lau K-HW Liang L Freeman TK Singer FR Stepans J . Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endrocrinol Metab 1990; 71: 442–51

Eastell R Hampton L Colwell A Green JR Assiri AMA Hesp R . Urinary collagen crosslinks are highly correlated with radioisotopic measurements of bone resorption. In: Cristiansen C Overgaard K , eds. Osteoporosis. Copenhagen: Osteopress ApS, 1990: 469–70

Calabresi E Lasagni L de Leonardis V Becorpi A Serio M Brandi ML . Comparison on immuno-and HPLC assays for the measurement of urinary collagen cross-links. J Endocrinol Invest 1994; 17: 625–9

Bouman AA Scheffer PG Ooms ME Lips P Netelenbos C . Two bone alkaline phosphatase assays compared with osteocalcin as a marker of bone formation in healthy elderly women. Clin Chem 1995; 41: 196–9

Steinberg KK Rogers TN . Alkaline phosphatase and osteocalcin in serum of normal subjects. Ann Clin Lab Sci 1987; 17: 241–50

Joerring S Jensen LT Anderson GR Johansen JS . Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 1992; 111: 265–7

Nyman MT Paavalainen P Forsius S Lamberg-Allardt C . Clinical evaluation of fracture healing by serum osteocalcin and alkaline phosphate. Ann Chir Gynaecol 1991; 80: 289–93

Power MJ Fottrell PF . Osteocalcin: Diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991; 28: 287–335

Lau KHW Onishi T Wergedal JE Singer FR Baylink DJ . Characterization and assay of tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption. Clin Chem 1987; 33: 458–62

Blumsohn A Colwell A Naylor K Eastell R . The effect of light and gamma irradiation on pyridinolines and telopeptides of type I collagen in urine. Clin Chem 1995; 41: 1195–7

Blumsohn A Herrington K Hannon RA Shao P Eyre DR Eastell R . The Effect of Calcium Supplementation on the Circadian Rhythm of Bone Resorption. J Clin Endocrinol Metab 1994; 79: 730–5

Blumsohn A Hannon RA Eastell R . Long term retest-reliability of biochemical markers of bone turnover in healthy postmenopausal women. J Bone Miner Res 1995; 10: S182

Morris HA Wishart JM Horowitz M Need AG Nordin BEC . The reproducibility of bone-related biochemical variables in post menopausal women Ann Clin Biochem 1990; 27: 562–8

Stevenson JC Cust MP Ganger KF Hillard TC Lees B Whitehead MI . Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265–9

Fuleihan GE Brown EM Curtis K Berger MJ Berger BM Gleason R . Effect of sequential and daily continuous hormone replacement therapy on indices of mineral metabolism. Arch Int Med 1992; 152: 1904–9

Blumsohn A Eastell R . Prediction of bone loss in postmenopausal women. Eur J Clin Invest 1992; 22: 764–6

Reeve J Pearson J Mitchell A Green J Nicholls A Justice J . Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Calcif Tissue Int 1995; 57: 105–10

Gardsell P Johnell O Nilsson BE . The predictive value of bone loss for fragility fractures in women: A longitudinal study over 15 years. Calcif Tissue Int 1991; 49: 90–4

Christiansen C Riis BJ Rodbro P . Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporosis Int 1990; 1: 35–40

Keen RW Harris PA Thompson PW James TI Sobnack R Perry LA . Early postmenopausal bone loss and biochemical markers. J Bone Miner Res 1994; 9: S399

Hannon R Blumsohn A Colwell A Peel NFA Eastell R . Biochemical markers of bone turnover and the prediction of spinal bone loss in older women. J Bone Miner Res 1994; 9: S399

Dresner-Pollak R Maitland LA Krasnow M Greenspan SL . Can biochemical markers predict bone loss in elderly women? J Bone Miner Res 1994; 9: S385

Hirsch L Watts N McLlwain H Rodriguez J Romanowicz A Daifotis A . Efficacy of aledronate to increase BMD is similar irrespective of baseline bone turnover and age. J Bone Miner Res 1995; 10: S350

Lufkin EG Wahner HW Ofallon WM Hodgson SF Kotowicz MA Lane AW . Treatment of osteoporosis with transdermal estrogen. Ann Int Med 1992; 117: 1–9

Storm T Thamsborg G Steiniche T Genant HK Sorenson OH . Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71